DE-104 ophthalmic solution + DE-104 vehicle
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Open-Angle Glaucoma
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Trial Timeline
— → —
NCT ID
NCT00656240About DE-104 ophthalmic solution + DE-104 vehicle
DE-104 ophthalmic solution + DE-104 vehicle is a phase 2 stage product being developed by Santen Pharmaceutical for Open-Angle Glaucoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00656240. Target conditions include Open-Angle Glaucoma, Ocular Hypertension.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00656240 | Phase 2 | Completed |
Competing Products
20 competing products in Open-Angle Glaucoma
Other Products from Santen Pharmaceutical
Eybelis ophthalmic solution 0.002%Approved
85
Aflibercept Injection [Eylea]Approved
85
STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%Phase 3
77
DE-117B Eye Drops + LatanoprostPhase 3
77
3% DE-089 ophthalmic solution + 0.1% sodium hyaluronate ophthalmic solutionPhase 3
77